Wells Fargo & Company MN Purchases 23,688 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Wells Fargo & Company MN boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 76.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 54,726 shares of the company's stock after purchasing an additional 23,688 shares during the period. Wells Fargo & Company MN's holdings in Cellebrite DI were worth $1,206,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in CLBT. R Squared Ltd acquired a new position in Cellebrite DI during the 4th quarter worth about $100,000. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the fourth quarter worth approximately $222,000. Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI during the fourth quarter valued at approximately $234,000. HighTower Advisors LLC acquired a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $274,000. Finally, Pictet Asset Management Holding SA bought a new position in Cellebrite DI in the 4th quarter worth approximately $283,000. 45.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on CLBT. Lake Street Capital increased their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, February 14th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Finally, Needham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday, April 2nd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $23.43.

Cellebrite DI Stock Performance

CLBT traded up $0.34 during midday trading on Friday, reaching $20.20. 475,493 shares of the company were exchanged, compared to its average volume of 1,412,183. The stock has a market capitalization of $4.84 billion, a P/E ratio of -14.54, a PEG ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The stock's 50-day simple moving average is $18.79 and its 200 day simple moving average is $20.16.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, research analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.